Healthcare Stocks to Watch: Martin Zweig's Latest Picks (Nov 2025)

Validea just dropped their latest stock screener based on Martin Zweig’s legendary growth strategy—here’s what made the cut in healthcare:

HCA Healthcare (HCA) - 69% confidence rating. This mega healthcare operator runs 190+ hospitals and 2,400 ambulatory sites across 20 states. Passes the P/E and earnings tests, but weak on revenue-to-EPS growth and earnings persistence. Classic play in the hospital management space.

Elevance Health (ELV) - Also 69% rated. Major health insurer with fingers in health benefits, pharmacy (CarelonRx), and healthcare services. Better balance sheet on most metrics, but sales growth lagging—typical insurance sector tension between premium growth and margin pressure.

Novartis (NVS) - 62% score. Swiss pharma giant juggling innovative drugs + generics (Sandoz). Solid earnings momentum but stumbling on revenue growth and long-term EPS expansion. Classic big pharma slowdown vibes.

RadNet (RDNT) & Select Medical (SEM) - Both 62% rated. RDNT runs 400+ imaging centers with AI diagnostics upside; SEM operates 100+ critical care + rehab hospitals. Both show strong revenue/earnings growth but red flags on P/E valuations and persistence.

Key takeaway: Zweig’s model hunting for accelerating growth + reasonable valuations. These stocks pass some tests, fail others—no slam dunks here. The 69-62% ratings suggest cautious interest, not conviction buys.

Reminder: Zweig’s 15-year track record averaged 15.9% annual returns. Not investment advice—do your own research.